These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 27315535)

  • 1. Chromatin targeting: A BET inhibitor workaround.
    Burns CJ
    Nat Chem Biol; 2016 Jun; 12(7):469-70. PubMed ID: 27315535
    [No Abstract]   [Full Text] [Related]  

  • 2. The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes.
    Conrad RJ; Fozouni P; Thomas S; Sy H; Zhang Q; Zhou MM; Ott M
    Mol Cell; 2017 Sep; 67(6):1001-1012.e6. PubMed ID: 28844864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospho-BRD4: transcription plasticity and drug targeting.
    Chiang CM
    Drug Discov Today Technol; 2016 Mar; 19():17-22. PubMed ID: 27769352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromatin-specific regulation of LEF-1-beta-catenin transcription activation and inhibition in vitro.
    Tutter AV; Fryer CJ; Jones KA
    Genes Dev; 2001 Dec; 15(24):3342-54. PubMed ID: 11751639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoiesis provides a BRD's eye view of BET protein function.
    Stonestrom AJ; Hsu SC; Werner MT; Blobel GA
    Drug Discov Today Technol; 2016 Mar; 19():23-28. PubMed ID: 27769353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of T
    Ghosh S; Lora JM
    Drug Discov Today Technol; 2016 Mar; 19():39-44. PubMed ID: 27769356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of BET proteins in castration-resistant prostate cancer.
    Fernandez-Salas E; Wang S; Chinnaiyan AM
    Drug Discov Today Technol; 2016 Mar; 19():29-38. PubMed ID: 27769354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.
    Crowe BL; Larue RC; Yuan C; Hess S; Kvaratskhelia M; Foster MP
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2086-91. PubMed ID: 26858406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromatin Starts to Come Clean.
    Tu S; LeRoy G; Reinberg D
    Mol Cell; 2016 Nov; 64(3):439-441. PubMed ID: 27814489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
    Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
    Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The House & Garden guide to chromatin remodelling.
    Martienssen R; Henikoff S
    Nat Genet; 1999 May; 22(1):6-7. PubMed ID: 10319848
    [No Abstract]   [Full Text] [Related]  

  • 18. Chromatin remodeling permits cardiac hypertrophy to develop.
    van Berlo JH
    J Mol Cell Cardiol; 2015 Dec; 89(Pt B):119-21. PubMed ID: 26523518
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-frequency promoter firing links THO complex function to heavy chromatin formation.
    Mouaikel J; Causse SZ; Rougemaille M; Daubenton-Carafa Y; Blugeon C; Lemoine S; Devaux F; Darzacq X; Libri D
    Cell Rep; 2013 Nov; 5(4):1082-94. PubMed ID: 24210826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.